Search

everythinglearnresearchcommunity

for

Search:↓

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

More research is needed to understand chemotherapy-induced hair loss and its phases.

The gel improves hair regrowth and reduces irritation in alopecia areata treatment.

Axitinib treatment turned a man's grey hair back to black.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

JAK inhibitors show promise in treating difficult skin diseases.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Further research is needed to develop effective cancer prevention strategies.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

Activating PPAR-γ signalling can protect hair follicle stem cells from damage caused by chemotherapy.

Krt15+ cells in mice can resist radiation, regenerate tissue, and start tumors, suggesting new cancer treatment targets.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

AHCC reduces hair loss and liver injury caused by chemotherapy in rodents.

Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.

RIPK1 inhibitors may help prevent alopecia areata by reducing immune cell activity.

A new mix of anthralin and calcipotriene might help treat severe hair loss.

YH0618 helps reduce chemotherapy-induced hair loss by targeting specific proteins and pathways.

Blocking TYK2 might be a new way to treat hair loss from alopecia areata.

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Protein Kinase C shows promise for cancer treatment, but more research is needed to develop effective inhibitors.

Abatacept may help some people with alopecia areata regrow hair.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.